CSBR CSBR
Company Profile ↓Company Overview
CSBR (CSBR) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 14.4% CAGR over the past five years.
Recent Developments
- Apr 2026 Revenue of $59.42M (+4.4% YoY); net profit $-1.18M.
- Trailing 12 Months Year-on-year growth — revenue +4.4%, earnings -125.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.41% |
| 1 Year: | 4.36% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -124.99% |
Stock Price Performance
| 1 Year: | -16.93% |
| 6 Months: | -25.67% |
| 3 Months: | -11.22% |
| 1 Month: | -9.86% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.4% over 5 years.
CONS
- Trading 36.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2013 | Jul 2013 | Oct 2013 | Jan 2014 | Jul 2014 | Oct 2014 | Jan 2015 | Jul 2015 | Oct 2015 | Jan 2016 | Jul 2016 | Oct 2016 | Jan 2017 | Jul 2017 | Oct 2017 | Jan 2018 | Jul 2018 | Oct 2018 | Jan 2019 | Jul 2019 | Oct 2019 | Jan 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Jul 2023 | Oct 2023 | Jan 2024 | Jul 2024 | Oct 2024 | Jan 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.43M | 6.74M | 7.62M | 9.01M | 9.55M | 10.12M | 10.81M | 11.25M | 11.79M | 13.19M | 13.74M | 14.28M | 12.77M | 12.56M | 11.57M | 12.02M | 14.06M | 13.49M | 17.04M | 13.99M | 15.04M | 16.56M |
| Operating Income | -720.00K | -766.00K | -1.70M | -1.41M | -3.73M | -3.67M | -3.42M | -2.90M | -2.49M | -2.37M | -2.52M | -493.00K | -1.40M | -619.00K | -70.00K | -67.00K | 481.00K | 275.00K | -370.00K | -614.00K | 291.00K | 433.00K | 24.00K | 7.00K | 982.00K | -175.00K | 263.00K | 830.00K | -284.00K | 7.00K | -2.46M | -2.55M | -1.96M | -2.58M | 1.33M | 732.00K | 4.50M | -527.00K | 185.00K | -276.00K |
| Net Income | -990.00K | -2.23M | -2.32M | -574.00K | -3.55M | -3.08M | -2.82M | -2.91M | -2.55M | -2.41M | -2.55M | -504.00K | -1.41M | -674.00K | -94.00K | -76.00K | 483.00K | 267.00K | -369.00K | -641.00K | 307.00K | 75.00K | 75.00K | 1.00K | 959.00K | -172.00K | 277.00K | 787.00K | -319.00K | -16.00K | -2.44M | -2.57M | -2.07M | -2.53M | 1.31M | 728.00K | 4.50M | -436.00K | 268.00K | -279.00K |
| Diluted EPS | - | - | -0.03 | -0.02 | -0.64 | -0.65 | -0.61 | -0.33 | -0.29 | -0.28 | - | - | - | -0.06 | -0.01 | -0.01 | 0.04 | 0.02 | -0.03 | -0.06 | 0.02 | 0.03 | 0.01 | 0.00 | 0.07 | -0.01 | 0.02 | 0.05 | -0.02 | 0.00 | -0.18 | -0.19 | -0.15 | -0.19 | 0.09 | 0.05 | 0.31 | -0.03 | 0.02 | -0.02 |
| R&D Expense | 592.00K | 402.00K | 677.00K | 535.00K | 1.42M | 1.25M | 1.09M | 1.10M | 919.00K | 999.00K | 1.21M | 1.01M | 998.00K | 1.12M | 1.11M | 1.04M | 1.09M | 1.19M | 1.27M | 1.30M | 1.34M | 1.39M | 1.60M | 1.65M | 1.88M | 2.30M | 2.30M | 2.18M | 2.89M | 2.60M | 3.20M | 2.79M | 2.52M | 2.19M | 1.45M | 1.69M | 1.72M | 2.08M | 2.62M | 2.27M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2011 | Apr 2012 | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 20.24M | 27.07M | 32.12M | 41.04M | 49.11M | 53.87M | 50.16M | 56.94M | 59.42M |
| Operating Income | -5.24M | -9.06M | -6.22M | -6.26M | -13.24M | -10.32M | -6.81M | -1.35M | 270.00K | -1.92M | 366.00K | 607.00K | -5.26M | -7.36M | 4.55M | -1.14M |
| Net Income | -3.80M | -8.66M | -6.33M | -7.41M | -13.14M | -10.45M | -6.88M | -1.48M | 128.00K | -2.09M | 362.00K | 548.00K | -5.33M | -7.28M | 4.70M | -1.18M |
| Diluted EPS | - | - | - | -0.11 | -2.20 | -1.20 | - | -0.13 | 0.01 | -0.18 | 0.02 | 0.04 | -0.39 | -0.54 | 0.33 | -0.08 |
| R&D Expense | 2.91M | 2.94M | 1.92M | 2.27M | 4.84M | 4.19M | 4.29M | 4.40M | 4.80M | 5.85M | 7.20M | 9.37M | 11.54M | 9.54M | 6.83M | 9.08M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2010 | Apr 2011 | Apr 2012 | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Jan 2021 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 12.65M | 6.92M | 11.65M | 8.87M | 12.05M | 5.78M | 8.01M | 8.08M | 11.27M | 20.75M | - | 27.59M | 35.38M | 34.31M | 26.13M | 32.34M | 26.99M |
| Total Equity | 1.58M | 19.00K | -5.28M | -9.21M | 3.20M | 8.06M | 238.00K | 400.00K | 3.00K | 2.14M | 5.10M | 8.09M | 7.43M | 9.10M | 4.64M | -1.90M | 3.77M | 3.94M |
| Cash & Equivalents | 2.57M | 10.46M | 4.75M | 9.56M | 5.89M | 9.36M | 2.58M | 3.29M | 856.00K | 3.24M | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 4.47M | 4.04M | 3.98M | 5.67M | 3.99M | 5.54M | 7.61M | 8.07M | 9.03M | 15.65M | 17.17M | 20.16M | 26.28M | 29.68M | 28.04M | 28.57M | 22.92M |
| Current Liabilities | - | 3.50M | 3.49M | 2.93M | 3.66M | 3.80M | 5.31M | 7.45M | 7.45M | 8.03M | 12.30M | 11.20M | 11.20M | 17.48M | 21.73M | 21.54M | 23.85M | 19.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2011 | Apr 2012 | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -54.00K | -5.23M | -4.29M | - | -9.63M | -6.41M | -2.84M | -1.23M | 1.86M | 2.90M | -1.68M | 6.50M | 3.97M | -6.14M | 7.39M | -4.47M |
| Investing Cash Flow | -84.00K | -519.00K | -57.00K | - | -114.00K | -322.00K | -766.00K | -1.23M | -834.00K | -2.22M | -3.17M | -2.38M | -2.87M | -836.00K | -389.00K | -540.00K |
| Financing Cash Flow | 8.08M | 97.00K | 9.14M | - | 13.21M | -42.00K | 4.32M | 13.00K | 1.20M | 4.42M | 1.20M | 207.00K | 11.00K | -527.00K | 170.00K | 99.00K |
| Capital Expenditure | -85.00K | -519.00K | -57.00K | -234.00K | -119.00K | -322.00K | -766.00K | -1.23M | -834.00K | -2.22M | -3.28M | -2.38M | -2.87M | -836.00K | -389.00K | -564.00K |
| Free Cash Flow | -139.00K | -5.75M | -4.35M | - | -9.75M | -6.73M | -3.61M | -2.46M | 1.03M | 685.00K | -4.96M | 4.11M | 1.10M | -6.97M | 7.00M | -5.04M |
| Share Buybacks | 1.03M | 0 | - | - | - | - | - | - | - | - | - | 0 | 74.00K | 634.00K | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Apr 2011 | Apr 2012 | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -6.7% | 1.0% | -6.0% | 0.9% | 1.2% | -9.8% | -14.7% | 8.0% | -1.9% |
| Net Margin % | - | - | - | - | - | - | - | -7.3% | 0.5% | -6.5% | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% | -2.0% |
| ROE % | -20,010.5% | 164.1% | 68.8% | -231.7% | -163.0% | -4,388.9% | -1,721.0% | -49,200.0% | 6.0% | -41.0% | 4.9% | 6.0% | -115.1% | 382.3% | 124.6% | -29.8% |
| ROCE % | -57.2% | -263.8% | -71.3% | -120.2% | -160.4% | -2,190.2% | -1,207.3% | -216.6% | 8.3% | -22.7% | 2.2% | 3.4% | -41.8% | -160.2% | 53.6% | -16.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CSBR
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNbnFPcDVsWTlOb2QwUWJETXFrUlZfLTZ1cVJsU1JqSFJVYTlYTjVsajNnWnRCUXkwU2F0VzRiQmZmTXFmbE8yRUVMZVREdHRlZWdNV2thNHFpemJGMXNzMDlvaUpubzREalpsRm82SktwWUlvMnhjRjc1emgtdDZUVmtWRmt1Y1VFS0hfOG…
Enterprise value to EBITDA forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOVUR4Rld3cU1LNnhPaExkWjdGTTNqSVNBUG9pdGhzazFTcWxQc0NXRVNjUk8tZWhmcmJ1SWdJVVRnNGMzX1c5UjZXalMxVFZPcUYwYWhrTERRckR2RWJkdGpHeFM2THo1dmJ0RUtEX1N5SXdvcGFBNXMyT0FzVDlReDNGNGx3aThhLUdWNj…
CHAMPIONS ONCOLOGY ($CSBR) Releases Q4 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOYWxHU2FvQWU4WFBOWllRRjJuMklKeEZwLWpsdTF1SHJBeExkWVBQcVNfQTg5LXpodEtEd3ZUcEQ2dkctUzg4RVRKOTU0Z2gwbkNfdE0xTEJEZG9jVV9fcTNCTHF3bGRyOERhTGwyREFtbUUySGIwSUdOSGlZam4tUVN1WDlnWTdFN1Vfdm…
Champions Oncology Schedules Year-End Results Call for 4:30 p.m. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRGVqZnJ4V2FuaWZkeTdhZ2g2SlNLRTRaamZUamNsdGJKZ3pGRVlRc2hOdlY1c2NwYmJvQ2tVcU9oV25ueG9tTVVPX2hpQ09mMGRJTUZyeUZldm9KdTJvQU1GMmk5MWxKU3c3OC1OTWJGbkZHM1J1TXdqT0JaNGNkU2hrRWk4NkhzWEVyS2…
Is Champions Oncology (NASDAQ:CSBR) In A Good Position To Invest In Growth? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPUzRzODhUTU4xYzJFSXBzUjIxVUhtRnY3T2JjT0E0SlVYTTBLQndqb3lObFRwNTNpODc2TVV5UDlyWERIbUVuSVd5NXU5LTloQVYtYjBtTmpvQml1UHdXZ2RRZXMzTVFHR0VLVWFlM0djLVdVVllNZ1RtRHRVWUlNRVpSVGh2R3JJZG5DaX…
CSBR|Champions Oncology Inc|Price:5.350|Chg%:-0.010 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1fUFMwcHUzbVhZQXltWG1iXzhkWE5kY1haRG5VNl9tTEE4aG1PaVFUZ21VdmpLd3RFZlZjaXZkQjhDSndhcjg2UW9IVndLcF82X09RLUNXT3JKdU9JaDRrM0hXVnQ2bnVJLUlPRndB?oc=5" target="_blank">CSBR|Champions Onco…
CSBR — Frequently Asked Questions
What is the current share price of CSBR?
As of 2026-08-05 17:25 PDT, CSBR trades at $5.30 on NASDAQ/NYSE. Its 52-week range is $5.26 to $8.30.
What is the P/E ratio of CSBR?
CSBR trades at a trailing price-to-earnings (P/E) ratio of -66.25.
What is the return on equity (ROE) of CSBR?
CSBR has a return on equity (ROE) of -29.83%. Its return on capital employed (ROCE) is -16.13%.
Is CSBR a good stock to buy?
This page provides a data-driven analysis of CSBR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.